Investor Relations
Sep 14, 2018
OPKO Confirms Resumption of Common Stock Trading on Nasdaq MORE >>
Sep 11, 2018
OPKO Comments on Continued Nasdaq Halt of Trading of Common Stock MORE >>
Sep 07, 2018
OPKO Comments on SEC Complaint MORE >>
Sep 04, 2018
OPKO Initiates RAYALDEE Phase 2 Trial in Dialysis Patients MORE >>

Press Releases

All Releases
OPKO Health, Inc. Set to Join Russell 3000 Index
Jun 17, 2008
MIAMI, Jun 17, 2008 (BUSINESS WIRE) -- OPKO Health, Inc. (AMEX:OPK) today announced that it is set to join the broad-market Russell 3000(R) Index when Russell Investment Group reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, 2008, according to a preliminary
OPKO Acquires Rights to Novel Phase II Agent to Treat Viral Conjunctivitis
Jun 12, 2008
--Novel Agent Has Demonstrated Good Safety and Antiviral Activity in Viral Conjunctivitis--
--Unique Combination of Anti-Infective and Anti-Inflammatory Properties Offers Potential for Broad-Based Ocular Applications--
Newly Published Study Shows OPKO's siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
Jun 03, 2008
- Study Published in Journal Molecular Vision -
- Results Show Good Distribution of Bevasiranib to Retina and RPE Cells after a Single Intravitreal Injection -
OPKO Health Acquires Company Developing Novel Glaucoma Therapy
May 07, 2008
-Vidus Ocular's Innovative Aquashunt(TM) Device Offers Potential Advantages-
-Glaucoma Affects 2.4 Million Americans and 60 Million People Worldwide-
OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib
Mar 18, 2008
-Second Issued Patent for Bevasiranib Broadly Covers siRNA Targeting of VEGF Expression, Further Strengthening OPKO's RNAi Intellectual Property Portfolio-
OPKO Health and Pathogenics Announce Data Publication Demonstrating the Potential Utility of NCT in a Severe Eye Infection
Feb 25, 2008
-In Vitro Data Shows OPKO's Formulation of NCT Has Promising Activity Against Acanthamoeba Keratitis, a Serious Ocular Infection- -Provides Additional Evidence That This Phase II Agent Has Good Tolerability and Broad Anti-Microbial Activity Against a Wide Range of Pathogens-
OPKO Health Announces Changes to Board of Directors
Jan 25, 2008
MIAMI, Jan 25, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- OPKO Health, Inc. (Amex: OPK) today announced the appointment of Thomas E. Beier and Richard C. Pfenniger, Jr. to its Board of Directors. The company also announced the resignation of former Board member David Eichler. Mr.
OPKO Health to Present at 2008 Wachovia Healthcare Conference
Jan 23, 2008
MIAMI, Jan 23, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- OPKO Health, Inc. (Amex: OPK) today announced that it will present at the 2008 Wachovia Healthcare Conference on Wednesday, January 30, 2008 at 11:15 am EST. The conference will be held at the Langham Hotel in Boston.
OPKO Health Appoints Industry Veteran Dr. Naveed Shams as Chief Medical Officer
Jan 14, 2008
MIAMI, Jan 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- OPKO Health, Inc. (Amex: OPK) today announced that Naveed Shams, M.D., Ph.D., has joined OPKO as its Chief Medical Officer and Senior Vice President of Research and Development. Dr.
OPKO's Bevasiranib Named One of Most Promising Drugs Recently Entering Phase III Trials
Dec 06, 2007
MIAMI, Dec 06, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- OPKO Health, Inc. (Amex: OPK) today reported that the gene silencing agent bevasiranib, OPKO's lead compound for the treatment of wet age-related macular degeneration (wet AMD), was named one of the top five most promising drugs
The Frost Group Invests $20 Million in OPKO Health
Dec 05, 2007
MIAMI, Dec 05, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- OPKO Health, Inc. (Amex: OPK) today announced that the members of The Frost Group, a private investment group controlled by Dr. Phillip Frost, Chairman and CEO of OPKO Health, have made a $20 million investment in OPKO.
OPKO Health Completes Acquisition of Ophthalmic Technologies, Inc.
Nov 29, 2007
MIAMI, Nov 29, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- OPKO Health Inc. (AMEX: OPK) today announced that it has completed the previously announced acquisition of Ophthalmic Technologies, Inc. (OTI), a privately owned Canadian company providing innovative ocular imaging systems to eye
OPKO Health Acquires Rights to Innovative Ocular Product to Prevent Serious Eye Infections
Oct 30, 2007
- Novel Ocular Product Is Specially Designed To Prevent Sight-Destroying Endophthalmitis - - Rising Number of Invasive Ocular Procedures and Use of Sutureless Ocular Surgery Are Associated With a Higher Incidence of Endophthalmitis -
OPKO Health Acquires Rights to Clinical Stage Compound for Dry Eye
Oct 10, 2007
MIAMI, Oct 10, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- OPKO Health Inc. (Amex: OPK) today announced that it has acquired exclusive worldwide rights for ophthalmic uses to a topical clinical stage compound with potential utility in the treatment of dry eye.
OPKO Health Appoints Pascal J. Goldschmidt To Board Of Directors
Oct 01, 2007
OPKO Health Appoints Pascal J. Goldschmidt To Board Of Directors MIAMI, FL– October 1, 2007– OPKO Health Inc. (AMEX: OPK) has announced the appointment of Pascal J. Goldschmidt, M.D. to its Board of Directors. Dr. Goldschmidt is the Senior Vice President for Medical Affairs and Dean of
OPKO Health to Present at UBS 2007 Global Life Sciences Conference
Sep 18, 2007
MIAMI, Sept. 18 /PRNewswire-FirstCall/ -- OPKO Health Inc. (Amex: OPK - News) today announced that it will present at the UBS 2007 Global Life Sciences Conference on Tuesday, September 25, 2007 at 11:30 am EDT. The conference will be held at the Grand Hyatt New York in New York City.
OPKO Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Aug 30, 2007
Groundbreaking Trial Is Designed to Compare Efficacy of Bevasiranib Administered Every 8 Weeks or 12 Weeks with Genentech's Lucentis® Administered Every 4 Weeks
OPKO Health, Inc. Announces Early Termination of Hart-Scott-Rodino Period for Proposed Purchase of Shares by Dr. Phillip Frost
Jul 12, 2007
Opko Health, Inc. Announces Early Termination of Hart-Scott-Rodino Period for Proposed Purchase of Shares by Dr. Phillip Frost MIAMI, FL– July 12, 2007– Opko Health Inc. (AMEX: OPK) today announced that that the U.S. Department of Justice has granted early termination of the waiting
OPKO Health Initiates Phase 3 Trial of Bevasiranib for the Treatment of AMD
Jul 11, 2007
-- Trial Designed to Compare Efficacy of Bevasiranib Administered Every 8 Weeks or 12 Weeks with Lucentis® Administered Every 4 Weeks --

-- Represents First-Ever Phase 3 Pivotal Trial of an RNAi Therapeutic --
Exegenics Changes Name to OPKO Health and Receives Approval for Its Shares to Trade on the American Stock Exchange Under the Symbol OPK
Jun 08, 2007
EXEGENICS CHANGES NAME TO OPKO HEALTH AND RECEIVES APPROVAL FOR ITS SHARES TO TRADE ON THE AMERICAN STOCK EXCHANGE UNDER THE SYMBOL OPK MIAMI, FL - June 8, 2007 - eXegenics, Inc. (OTC BB: EXEG) today announced that it has completed its name change to Opko Health Inc.
Displaying 341 - 360 of 363